Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center

Articles by Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Dr. Le on the Safety of Twice-Daily Poziotinib in EGFR- or HER2 Exon 20–Positive NSCLC

ByXiuning Le, MD, PhD

April 10th 2021

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

ByXiuning Le, MD, PhD

July 13th 2020

Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

ByXiuning Le, MD, PhD

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Xiuning Le, MD, PhD

Articles by Xiuning Le, MD, PhD

Dr. Le on the Safety of Twice-Daily Poziotinib in EGFR- or HER2 Exon 20–Positive NSCLC

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma